MSTN and hyperinsulinemic hypoglycemia, familial, 4: While genetic myostatin deficiency was shown to enhance bone volume, to our knowledge the data presented here are the first examples of a selective myostatin inhibitor having beneficial effects on bone in a therapeutic setting (74,76).